摘要
目的探讨非小细胞肺癌(NSCLC)患者外周血游离DNA的EGFR基因突变与靶向药物疗效的相关性。方法选取60例NSCLC患者,均行外周血游离DNA EGFR基因检测,根据检测结果分组,EGFR突变型为观察组(n=13), EGFR野生型为对照组(n=47),两组均予以吉非替尼行EGFR-TKI治疗,比较两组的客观缓解率(ORR)、疾病控制率(DCR),分析EGFR基因突变与疗效的相关性。结果两组的ORR比较无显著差异(P>0.05),观察组的DCR显著高于对照组(P <0.05)。Logistic回归分析结果显示,EGFR基因突变是EGFR-TKI治疗疗效的重要影响因素(P <0.05)。结论 NSCLC患者外周血游离DNA的EGFR基因突变与靶向药物治疗疗效具有相关性,能够为临床提供指导。
Objective To explore the correlation between EGFR gene mutation of free DNA in peripheral blood and efficacy of targeted drug in patients with non-small cell lung cancer(NSCLC).Methods 60 NSCLC patients were selected.All patients received test of EGFR gene of free DNA in peripheral blood.All cases were grouped according to the test results:EGFR mutant type was the observation group(n=13),and EGFR wild type was the control group(n=47).Both groups were given gefitinib for EGFR-TKI treatment,and the objective response rate(ORR)and disease control rate(DCR)were compared between two groups.The correlation between EGFR gene mutation and efficacy was analyzed.Results No significant difference was found in ORR between two groups(P>0.05),and the DCR of observation group was significantly higher than that of control group(P<0.05).Logistic regression analysis showed that EGFR gene mutation was an important factor influencing the treatment efficacy of EGFR-TKI(P<0.05).Conclusions EGFR gene mutation of free DNA in peripheral blood of NSCLC patients is related to the treatment efficacy of targeted drug,which can provide guidance in clinic.
作者
温坚
何志江
刘传勇
刘云军
WEN Jian;HE Zhijiang;LIU Chuanyong;LIU Yunjun(^nd Department of Oncology,Maoming People's Hospital,Maoming 525000,China)
出处
《临床医学工程》
2020年第6期727-728,共2页
Clinical Medicine & Engineering
基金
茂名市科技计划项目(项目编号:2017026)。
